Drug Profile
Retigabine - Bausch Health Companies/GlaxoSmithKline
Alternative Names: ADD-230001; AW21-360; D-20443; D-20443 dihydrochloride; D-23129; Ezogabine; Ezogabine-XR; GKE 841; GW-582892X; Potiga; Retigabine-XR; Trobalt; WAY-143841Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Meda
- Developer Bausch Health Companies; GlaxoSmithKline; Harvard University; Massachusetts General Hospital; The ALS Association; Valeant Pharmaceuticals International
- Class Antiepileptic drugs; Carbamates; Fluorobenzenes; Phenylenediamines; Small molecules
- Mechanism of Action GABA A receptor agonists; KCNQ potassium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Market Withdrawal Partial epilepsies
- Discontinued Amyotrophic lateral sclerosis; Lennox-Gastaut syndrome; Postherpetic neuralgia
Most Recent Events
- 17 Jul 2018 GlaxoSmithKline terminates a phase III extension trial in Partial seizures (Adjunctive treatment) in Australia, France, Israel, Poland, Ukraine, Russia, South Africa, United Kingdom, Hungary, Belgium, Spain and Germany as there was no longer any benefit in collecting data since retigabine had been withdrawn from market (PO) (NCT00310388)
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
- 01 Feb 2018 Massachusetts General Hospital, in collaboration with GlaxoSmithKline, ALS Association and Harvard University completes a phase II trial in Amyotrophic lateral sclerosis in USA (PO) (NCT02450552)